(GuruFocus, December 15, 2009) These are companies among the largest price percentage drops. They typically have one misfortune or another, some legitimate, some not.
1. Transition Therapeutics Inc. (TTHI, Financial)
TTHI is down $3.55 (44.88%) per share at $4.46.
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine.
The company announced change in the trial of one of its drugs. In Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer's disease, patients will be withdrawn immediately from the study in the two higher dose groups. The study will continue unchanged for patients who are assigned to the lower dose and placebo groups. The AD251 study will be modified to dose patients only at 250mg twice daily. Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses, the firm said.
An analyst with Roth Capital downgraded the stock from buy to hold.
The stock has been very volatile of late. Sunesis Pharmaceuticals last week reported positive Phase II data for its leukemia drug voreloxin. On Friday, a Reuters article offered speculation about a possible partnership on the drug and the positive trial data. Sunesis Pharmaceuticals' CFO Eric Bjerkholt told Reuters that the company was exploring alternatives for funding, and partnerships is one of the alternatives that are being explored.
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases.
Jean-Marie Eveillard has a small position in the company.
Back in July, we saw 10% Owner Pincus Equity Partners Warburg sold amore than 0ne million shares.
3. GenCorp Inc. (GY, Financial)
GY is down $1.29 (15.27%%) per share at $7.16.
GenCorp Inc. (GY) announced today that it intends to offer, subject to market and other conditions, up to $125 million aggregate principal amount of convertible subordinated debentures.
GenCorp is technology-based manufacturing company headquartered in Sacramento, California. Its businesses are concentrated in three principal industries: aerospace and defense, pharmaceutical fine chemicals, and automotive.
John Keeley and Michael Price own shares in the company.
4. Cyclacel Pharmaceuticals Inc. (CYCC, Financial)
CYCLACEL is a biopharmaceutical company. CYCC is down $0.20 (14.70%) per share at $1.16
Cyclacel Pharmaceuticals announced today that the Company recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss a randomized Phase 3 study design for Cyclacel's oral sapacitabine capsules in acute myeloid leukemia (AML) and separately in myelodysplastic syndromes (MDS).
It seems to be at least neutral if not positive news and does not explain the price drop.
Wilbur Ross owns 890,213 shares of the company.
Recently, 10% Owner Austin W & Greenhouse Da Marxe has been buying shares in the open market since September.
Financial information services provider FactSet Research Systems Inc (FDS) projected second-quarter results slightly below estimates, as customers remain cautious on spending, sending shares down more than 11 percent.
FactSet Research Systems Inc. supplies global economic and financial data to analysts, investment bankers and other financial professionals.
FactSet Research Systems Inc. is owned by Jean-Marie Eveillard, Ron Baron and John Hussman.
Company insider have been selling of late. CEO & Chairman Philip A Hadley, CFO & Treasurer Peter G Walsh and other other company insiders all dumped shares in the market.
GuruFocus provides real time information and insights of Investment Gurus such as Warren Buffett and Company Insiders for Premium Members. If you are not a premium member, click here to sign up or upgrade. 7-Day Free Trial is available.
1. Transition Therapeutics Inc. (TTHI, Financial)
TTHI is down $3.55 (44.88%) per share at $4.46.
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine.
The company announced change in the trial of one of its drugs. In Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer's disease, patients will be withdrawn immediately from the study in the two higher dose groups. The study will continue unchanged for patients who are assigned to the lower dose and placebo groups. The AD251 study will be modified to dose patients only at 250mg twice daily. Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses, the firm said.
An analyst with Roth Capital downgraded the stock from buy to hold.
2. Sunesis Pharmaceuticals Inc. (SNSS, Financial)
SNSS is down $0.35 (16.75%) per share at $1.74.The stock has been very volatile of late. Sunesis Pharmaceuticals last week reported positive Phase II data for its leukemia drug voreloxin. On Friday, a Reuters article offered speculation about a possible partnership on the drug and the positive trial data. Sunesis Pharmaceuticals' CFO Eric Bjerkholt told Reuters that the company was exploring alternatives for funding, and partnerships is one of the alternatives that are being explored.
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases.
Jean-Marie Eveillard has a small position in the company.
Back in July, we saw 10% Owner Pincus Equity Partners Warburg sold amore than 0ne million shares.
3. GenCorp Inc. (GY, Financial)
GY is down $1.29 (15.27%%) per share at $7.16.
GenCorp Inc. (GY) announced today that it intends to offer, subject to market and other conditions, up to $125 million aggregate principal amount of convertible subordinated debentures.
GenCorp is technology-based manufacturing company headquartered in Sacramento, California. Its businesses are concentrated in three principal industries: aerospace and defense, pharmaceutical fine chemicals, and automotive.
John Keeley and Michael Price own shares in the company.
4. Cyclacel Pharmaceuticals Inc. (CYCC, Financial)
CYCLACEL is a biopharmaceutical company. CYCC is down $0.20 (14.70%) per share at $1.16
Cyclacel Pharmaceuticals announced today that the Company recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss a randomized Phase 3 study design for Cyclacel's oral sapacitabine capsules in acute myeloid leukemia (AML) and separately in myelodysplastic syndromes (MDS).
It seems to be at least neutral if not positive news and does not explain the price drop.
Wilbur Ross owns 890,213 shares of the company.
Recently, 10% Owner Austin W & Greenhouse Da Marxe has been buying shares in the open market since September.
5. FactSet Research Systems Inc. (FDS, Financial)
FDS is down $8.94 (11.75%) per share at $67.12.Financial information services provider FactSet Research Systems Inc (FDS) projected second-quarter results slightly below estimates, as customers remain cautious on spending, sending shares down more than 11 percent.
FactSet Research Systems Inc. supplies global economic and financial data to analysts, investment bankers and other financial professionals.
FactSet Research Systems Inc. is owned by Jean-Marie Eveillard, Ron Baron and John Hussman.
Company insider have been selling of late. CEO & Chairman Philip A Hadley, CFO & Treasurer Peter G Walsh and other other company insiders all dumped shares in the market.
GuruFocus provides real time information and insights of Investment Gurus such as Warren Buffett and Company Insiders for Premium Members. If you are not a premium member, click here to sign up or upgrade. 7-Day Free Trial is available.
